We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current GNOM market cap is 64.6M. The company's latest EPS is USD 0.4702 and P/E is 18.78.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End 30 November 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 60k | 323k | 572k | 300k | 243k |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | 17.21M | -34.81M | -79.05M | -58.84M | 3.44M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End 30 November 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 84.48M | 262.33M | 212.3M | 97.1M | 84.39M |
| Total Liabilities | 2.53M | 6.76M | 2.95M | 4.07M | 5.23M |
| Total Equity | 81.95M | 255.57M | 209.34M | 93.03M | 79.16M |
| Market Cap | 64.6M |
| Price to Earnings Ratio | 18.78 |
| Price to Sales Ratio | 265.96 |
| Price to Cash Ratio | 684.5 |
| Price to Book Ratio | 0.82 |
| Dividend Yield | - |
| Shares Outstanding | 7.31M |
| Average Volume (1 week) | 53.77k |
| Average Volume (1 Month) | 89.95k |
| 52 Week Change | -24.54% |
| 52 Week High | 11.88 |
| 52 Week Low | 8.59 |
| Spread (Intraday) | 1.2 (12.37%) |
| Company Name | Global X Genomics and Biotechnology |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https:// |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
